[Combination of L-dopa and sulpiride in the treatment of Parkinson's disease].
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D013469:Sulpiride / Q000009:adverse effects / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D004295:Dihydroxyphenylalanine; D013469:Sulpiride
L'association de la L-dopa et du sulpiride dans le traitement de la maladie de Parkinson